French Institute of Health, Medical Research and Assistance Publique Hopitaux De Paris | Date: 2016-11-23
The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41.
Institute Pasteur Of Lille, French Institute of Health, Medical Research and National University of Singapore | Date: 2016-11-17
The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine.
Technion Research & Development Foundation Ltd., French Institute of Health and Medical Research | Date: 2016-12-14
A method of generating a population of corneal epithelial cells is disclosed. The method comprises culturing human pluripotent stem cells in corneal fibroblast-conditioned medium on a solid surface comprising an extracellular matrix component thereby generating the population of corneal epithelial cells. Isolated cell populations and corneal tissues are also disclosed, as well as uses thereof.
French Institute of Health, Medical Research, University Paris - Sud and University of Bordeaux 1 | Date: 2016-12-28
The present invention relates to polypeptides and their uses as apelin inhibitors. More particularly, the present invention relates to a polypeptide comprising the sequence as set forth in SEQ ID NO:1 wherein at least one arginine residue at position 18, 19, 22 or 23 has been substituted or deleted.
Ose Immunotherapeutics, French Institute of Health and Medical Research | Date: 2016-12-21
The invention relates to humanized antibodies directed against the human lymphocyte receptor CD28. When used in a monovalent form these antibodies are antagonists, i.e. capable of blocking of the CD28/B7 interaction, without activating CD28. These antibodies can be used in particular as therapeutic agents for blocking T cell activation through the CD28 receptor.
Lille 2 University of Health, Law, French Institute of Health, Medical Research and Lille University Hospital Center | Date: 2015-06-11
The invention relates to compounds of formula (I) or the pharmaceutically acceptable solvates thereof, as well as to the use thereof as a drug.
Institute Curie, French Institute of Health and Medical Research | Date: 2015-02-10
The present invention relates to the use of modulators of Mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.
Agv Discovery, French Institute of Health, Medical Research, French National Center for Scientific Research and Montpellier University | Date: 2017-05-24
Vaiomer, French Institute of Health and Medical Research | Date: 2017-05-31
The present invention concerns polydextrose for use for preventing and/or treating heart failure in a subject.
French Institute of Health and Medical Research | Date: 2016-11-11
The Invention relates to an ex vivo method of diagnosing or predicting a hereditary spastic paraplegias (HSP), in a subject, which method comprises detecting a mutation in the ZFYVE26 gene or protein (spastizin), wherein said mutation is indicative of a hereditary spastic paraplegias (HSP).